ClinicalTrials.gg
Status unknownNCT03485560Updated Apr 2, 2018

Revitalization of Damaged Skin Due to Chronic Skin Diseases

An Early Phase 1 interventional study of ACE CSD in Chronic Eczema, Psoriasis and Atopic Dermatitis, sponsored by Ace Cells Lab Limited. Status unknown at 2 sites in 2 countries. Per ClinicalTrials.gov, last updated 2018-04-02.

Sponsored by Ace Cells Lab Limited · Early Phase 1, Interventional, and Treatment

How we know

The sponsor has not verified this record recently (last verified Nov 2017), so the status shown — last known as Not yet recruiting — may be out of date.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Early Phase 1
Study type
Interventional
Enrollment
200
Allocation
Not applicable
Sex
All
01

Study summary

Chronic skin disease lead to skin damage and disfiguring to the patient skin. Sometimes, achieving normal skin is not possible by the normal traditional treatment, this study is focusing on use of ACE CSD formula which is mixture of natural peptides and herbs. the main aim is to restore the normal skin appearance for the patient and control the episodes of flare.

Read the detailed description

Psoriasis is a chronic, immune mediated (type 2 and type 17) chronic skin disease. The production of the immune proteins that leads to continuous inflammatory mediated process. The result of chronic inflammation is they hyper keratotic layer of skin which gets attacks of atopic dermatitis leading to symptoms of itching, pruritis and in situ bleeding.

ACE CSD, with the multiple factors that mediates the immune response and control the protein receptors, in addition to the multiple regeneration peptides that are specifically extracted from healthy skin of newly born sheep; in addition to multiple Chinese herbs that contains different anabolic factors was tested to be able to regenerate the damaged skin and locally modulate the immunity reactions so the skin can regenerate fully to replace the damaged skin with normal healthy skin.

02

Conditions studied

  • Chronic Eczema
  • Psoriasis
  • Atopic Dermatitis

Keywords

  • chronic skin disease
  • psoriasis
  • Eczema
  • atopic dermatitis
03

In context

Psoriasis

2,032 studies on the registry are indexed under Psoriasis; 278 are open to participants now.

This study's planned enrollment of 200 is above the median of 75 across 1,568 interventional studies indexed under Psoriasis.

Browse Psoriasis studies →

Lead sponsor

Ace Cells Lab Limited is the lead sponsor of 4 studies on the registry; 3 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Chronic skin condition lasts for more than 1 year.
  • tried traditional treatment with limited or without effect.
  • not on for at least 6 weeks.

Exclusion criteria

Exclusion Criteria:

  • patients on .
  • patients intolerable to protein or allergic to proteins
  • during pregnancy or lactation
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Early Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
200 participants (estimated)

Study arms

  • Experimental
    internvention of Chrinic skin conditions

    All cases of chronic skin conditions will be included to measure the effect on the 3 of them and whihc one will respond to the treatment better

    Combination Product: ACE CSD

Interventions

  • Combination productACE CSD

    Topical application of the ACE CSD 4 times daily.

    Also known as: ACE Skin immune

06

What researchers measure

Primary outcomes

  1. Regeneration of the damaged skin lesion

    Complete regeneration of the affected skin lesions from the skin disease.

    Time frame: 6 - 9 months

Secondary outcomes

  1. Flare control

    During the attacks of flare, the regenerated skin does not get affected nor show erythematous reaction

    Time frame: 1-3 months

07

Study locations

2 sites
  • ACE cells Lab Europe Doo
    Belgrade, 11000, Serbia
  • ACE Cells Lab Limited
    Nottingham, Nottinghamshire NG90 6BH, United Kingdom
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for May 2018; primary completion for Nov 2018, 6 months later.

Of 137 industry-sponsored phase 1 interventional studies under Psoriasis, half reached primary completion within 10 months of starting (the median), counting those still running; a quarter within 4 and three quarters within 16. This study's planned 6 months is below that.

Counting every sponsor, half of 155 studies reached it within 10 months; a quarter within 5 and three quarters within 17.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 7, 2017
First posted
Apr 2, 2018
StartEst.
May 1, 2018
Primary completionEst.
Nov 1, 2018
CompletionEst.
Jan 1, 2019
Last update
Apr 2, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 2, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03485560
Lead sponsor
Ace Cells Lab Limited
Responsible party
Sponsor
First posted
Apr 2, 2018
Start date
May 1, 2018 (estimated)
Primary completion
Nov 1, 2018 (estimated)
Completion
Jan 1, 2019 (estimated)
Last update
Apr 2, 2018

Study contacts

Dr. Alaa Abdelkarim MF Mohammed
Contact
dralaakarim@gmail.com
+447473922553
Dr. Diana Diana, MsC Dermatology
Contact
dr.dianadiana@outlook.com
Dr. Diana Diana, MSc Dermatology
principal investigator · ACE cells Lab europe DOO

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Nov 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion